Masteron (Mast)
DHT-Derived Anabolic Steroid | Hardening & Anti-Estrogenic
Community Research
Join others researching Masteron — share findings, ask questions, and learn from real experiences
Masteron (drostanolone) is a synthetic dihydrotestosterone (DHT)-derived anabolic-androgenic steroid originally developed and marketed as Masteril and Drostanolone Propionate for the treatment of inoperable breast cancer in postmenopausal women. It received FDA approval for this indication in the 1970s but has since been discontinued from pharmaceutical markets. Structurally, drostanolone is DHT with a 2-alpha-methyl group, which increases its anabolic potency and protects it from metabolic breakdown by 3-alpha-hydroxysteroid dehydrogenase in muscle tissue. As a DHT derivative, Masteron does not aromatize to estrogen and exhibits mild anti-estrogenic properties, likely through competitive inhibition at the aromatase enzyme or direct antagonism at the estrogen receptor. This makes it uniquely suited for cutting and contest preparation cycles where a dry, hard, and grainy physique is desired. Masteron is not a mass-building compound; its primary value lies in aesthetic enhancement, estrogen management, and synergy with other anabolic agents. It is available in two ester forms: the short-acting propionate (original pharmaceutical form) and the longer-acting enanthate (underground lab formulation). Effective results are most visible at lower body fat percentages, typically below 12-15%, where its hardening and drying effects become pronounced.
Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, eliminating estrogen-related side effects such as water retention and gynecomastia from the compound itself. Masteron exhibits anti-estrogenic activity through a dual mechanism: it competitively inhibits aromatase enzyme activity (reducing conversion of other aromatizable steroids like testosterone to estradiol) and may act as a weak antagonist at estrogen receptors in breast tissue, which was the basis for its historical use in breast cancer treatment. This anti-estrogenic property is the reason Masteron can reduce or eliminate the need for dedicated aromatase inhibitors when stacked with testosterone. Unlike testosterone, drostanolone is not a substrate for 5-alpha reductase, as it is already a DHT derivative and cannot be further reduced. This means its full androgenic potency is expressed in all tissues, including hair follicles and the prostate, which accounts for its significant hair loss potential in genetically predisposed individuals. The 2-alpha-methyl modification prevents inactivation by 3-alpha-hydroxysteroid dehydrogenase in muscle, allowing drostanolone to exert its full anabolic effect at the tissue level rather than being rapidly metabolized to inactive forms as unmodified DHT would be.
Molecular Data
Research Indications
Drostanolone propionate was FDA-approved for the treatment of advanced, inoperable breast cancer in postmenopausal women. Its anti-estrogenic properties provided tumor-suppressive effects in hormone-receptor-positive breast cancers. This indication has been superseded by modern selective estrogen receptor modulators and aromatase inhibitors, and pharmaceutical production has been discontinued.
Masteron is primarily used during cutting phases and pre-contest preparation to achieve a hard, dry, and defined physique. Its anti-estrogenic and non-aromatizing properties eliminate water retention from the compound, while its androgenic effects promote muscle hardness and vascularity. Most effective when body fat is below 12-15%.
At moderate doses alongside a testosterone base, Masteron can improve body composition by promoting a leaner, more vascular appearance without significant scale weight changes. Commonly used in recomposition phases where the goal is visual improvement rather than mass gain.
Masteron's mild anti-estrogenic properties allow it to reduce circulating estradiol levels when stacked with aromatizable compounds like testosterone. Some users employ it specifically to minimize or eliminate the need for pharmaceutical aromatase inhibitors, which can negatively impact lipids, joint comfort, and bone mineral density.
Dosing Protocols
Masteron is administered exclusively via intramuscular injection. Two ester formulations exist: drostanolone propionate, the original pharmaceutical preparation with a short half-life requiring frequent injections (every other day or daily), and drostanolone enanthate, a longer-acting formulation produced by underground labs that permits less frequent dosing (twice weekly). Propionate remains the more widely used and available form.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cutting / Aesthetic Enhancement | 300-400 mg/week | Every other day (propionate) or 2x per week (enanthate) | Intramuscular |
| Contest Preparation | 400-500 mg/week | Every other day or daily (propionate) | Intramuscular |
| AI Replacement / Estrogen Management | 200-300 mg/week | Every other day (propionate) or 2x per week (enanthate) | Intramuscular |
Reconstitution Instructions
- Pre-filled drostanolone vial (typically 100 mg/mL propionate or 200 mg/mL enanthate in carrier oil)
- Syringes (1 mL or 3 mL)
- Drawing needle (18-21 gauge)
- Injection needle (22-25 gauge for IM)
- Alcohol swabs
- Sharps container
- 1 Wash hands thoroughly and prepare a clean work surface
- 2 Wipe vial stopper with alcohol swab and allow to dry
- 3 Draw air into syringe equal to the volume of drostanolone to be withdrawn
- 4 Insert drawing needle through vial stopper and inject air to equalize pressure
- 5 Invert vial and withdraw the prescribed dose, tapping to remove air bubbles
- 6 Switch to injection needle (do not inject with drawing needle)
- 7 Clean injection site with alcohol swab in circular motion outward
- 8 Insert needle at 90-degree angle into ventrogluteal, vastus lateralis, or deltoid muscle
- 9 Aspirate briefly (optional per current guidelines), then inject slowly over 10-30 seconds
- 10 Withdraw needle, apply gentle pressure with gauze, dispose of needle in sharps container
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
- Acne and increased skin oiliness, particularly on the back and shoulders
- Suppression of natural testosterone production (requires PCT or ongoing TRT)
- Injection site pain or discomfort (more common with propionate ester)
- Mild aggression or irritability from elevated androgenic activity
- HDL cholesterol suppression and adverse lipid profile changes
Stop Signs - Discontinue if:
- Severe chest pain, tightness, or pressure
- Sudden shortness of breath or difficulty breathing
- Significant scalp hair loss progressing rapidly beyond baseline shedding
- Swelling, warmth, or pain in one leg (potential deep vein thrombosis)
- Severe or persistent headaches with visual disturbances
- Signs of stroke: sudden numbness, confusion, trouble speaking, loss of coordination
- Persistent urinary difficulty or pain (prostate-related)
Contraindications
- Prostate cancer (active or history of hormone-sensitive prostate cancer)
- Breast cancer in males
- Pregnancy or potential for pregnancy (causes virilization of female fetus)
- Known hypersensitivity to drostanolone or any formulation components
- Severe hepatic impairment
- Pre-existing significant hair loss where further androgenic exposure is unacceptable
- Polycythemia (hematocrit above 54% at baseline)
- Uncontrolled cardiovascular disease or severe dyslipidemia
Quality Checklist
Good Signs
- Clear, pale yellow to yellow oil with no visible particles or cloudiness
- Proper labeling with concentration (typically 100 mg/mL propionate or 200 mg/mL enanthate), ester type, and expiration date
- Intact rubber stopper with no signs of prior puncture
- Oil draws smoothly with appropriate viscosity
- Product sourced from reputable supplier with third-party testing (note: no pharmaceutical-grade Masteron currently in production)
Warning Signs
- Concentration claims above 150 mg/mL for propionate or 250 mg/mL for enanthate (higher concentrations often cause post-injection pain)
- Vial label with spelling errors, misaligned printing, or unprofessional appearance
- Oil appears slightly darker than expected but is otherwise clear
- No third-party analytical testing documentation available
Bad Signs
- Cloudy, discolored, or particulate-containing solution (contamination risk)
- Crashed product (crystallized steroid visible in vial)
- Broken or missing tamper-evident seal on vial
- No labeling, incorrect labeling, or missing expiration date
- Pain, redness, or swelling at injection site lasting more than 72 hours (potential infection or abscess)
- Product sourced without any testing or third-party verification
References
- Drostanolone Propionate (Masteril): A Short Review of a Discontinued Breast Cancer DrugRaynaud, J.P.Journal of Steroid Biochemistry and Molecular Biology (1988)
Review of drostanolone propionate's clinical use in inoperable breast cancer, documenting its anti-estrogenic properties and mechanisms. Demonstrated objective tumor regression in a subset of postmenopausal patients with hormone-receptor-positive disease, supporting its classification as a hormonal antineoplastic agent.
- Androgens and the Treatment of Breast CancerGoldenberg, I.S.Cancer (1964)
Early clinical report on the use of androgenic steroids including drostanolone in breast cancer treatment. Documented objective response rates and the dual mechanism of direct anti-tumor effects and anti-estrogenic activity that formed the basis for FDA approval.
- Anabolic-Androgenic Steroid Use and Body Image in Men: A Growing Concern for CliniciansKanayama, G., Hudson, J.I., Pope, H.G.Psychotherapy and Psychosomatics (2012)
Comprehensive review covering the pharmacology and health effects of anabolic-androgenic steroids including DHT derivatives like drostanolone. Documented dose-dependent cardiovascular, hepatic, and endocrine adverse effects associated with long-term use.
- Adverse Effects of Anabolic Androgenic Steroids on Cardiovascular SystemAchar, S., Rostamian, A., Narayan, S.M.Southern Medical Journal (2010)
Review of cardiovascular toxicity associated with anabolic steroids, documenting HDL cholesterol suppression, left ventricular hypertrophy, and thrombotic risk. Emphasized the importance of cardiovascular monitoring in individuals using DHT-derived compounds like Masteron.
- Comparison of the Pharmacokinetics of Testosterone Propionate and Testosterone EnanthateNieschlag, E., Behre, H.M.Testosterone: Action, Deficiency, Substitution (Cambridge University Press) (2004)
Pharmacokinetic analysis of propionate versus enanthate ester formulations applicable to understanding drostanolone ester behavior. Propionate demonstrates a half-life of 1-3 days with rapid peak levels, while enanthate extends the half-life to 7-10 days, directly informing injection frequency protocols for both Masteron esters.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.